Loading clinical trials...
Loading clinical trials...
A Multicenter, Open, Randomized, Controlled Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA (L-asparaginase Encapsulated in Red Blood Cells, Eryaspase) Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Elderly Patients, Unfit for Intensive Chemotherapy
Conditions
Interventions
GRASPA
Locations
21
France
Hôpital l'Archet 1
Nice, Alpes Maritimes, France
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France
Centre hospitalier Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Institut Paoli Calmettes
Marseille, Bouche Du Rhone, France
Hôpital JEAN MINJOZ
Besançon, Doubs, France
Hopital Morvan
Brest, Finistere, France
Start Date
February 1, 2013
Primary Completion Date
November 10, 2017
Completion Date
November 10, 2017
Last Updated
February 21, 2022
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
ERYtech Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions